1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,250 | 1,350 | 22.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.12.24 | What's Next for Biopharma? Tevogen's (TVGN) AI Breakthrough at the J.P. Morgan Conference | 5 | Insider Monkey | ||
| 20.12.24 | Tevogen Bio (TVGN) Advances AI-Driven Immunotherapy with New Patent Filing | 1 | Insider Monkey | ||
| 19.12.24 | Tevogen Bio Inc: Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth ... | 2 | GlobeNewswire (USA) | ||
| 05.12.24 | Tevogen Bio Inc: Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame | 2 | GlobeNewswire (USA) | ||
| 26.11.24 | Tevogen Bio Inc: Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy | 2 | GlobeNewswire (USA) | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 21.11.24 | Tevogen Bio Inc: Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value | 78 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically... ► Artikel lesen | |
| 19.11.24 | Tevogen Bio Holdings reports Q3 results | 6 | Seeking Alpha | ||
| 19.11.24 | Tevogen Bio Inc: Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model | 114 | GlobeNewswire (Europe) | Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 and 2023, respectively.Significantly... ► Artikel lesen | |
| 19.11.24 | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 15.11.24 | Tevogen Bio Holdings Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 14.11.24 | Tevogen Bio Inc: Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials | 1 | GlobeNewswire (USA) | ||
| 11.11.24 | Tevogen Bio Partners with Microsoft Corporation (MSFT) to Leverage Advanced AI Tools for Biotech Research in Healthcare | 6 | Insider Monkey | ||
| 08.11.24 | Tevogen Bio Inc: Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations | 101 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically... ► Artikel lesen | |
| 06.11.24 | Tevogen Bio partners Microsoft for HPV treatment | 12 | Pharmaceutical Technology | ||
| 05.11.24 | Tevogen Bio Inc: Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability | 3 | GlobeNewswire (USA) | ||
| 05.11.24 | Tevogen Bio Inc: Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920 | 3 | GlobeNewswire (USA) | ||
| 04.11.24 | Tevogen Bio Inc: Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support | 2 | GlobeNewswire (USA) | ||
| 31.10.24 | Tevogen partners with Microsoft to speed up drug development | 8 | Investing.com | ||
| 31.10.24 | Tevogen kooperiert mit Microsoft zur Beschleunigung der Medikamentenentwicklung | 9 | Investing.com Deutsch | ||
| 31.10.24 | Tevogen Bio Inc: Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs | 4 | GlobeNewswire (USA) |
Seite:
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 46,035 | +0,98 % | Qiagen zahlt Ende Januar 1,26 US-Dollar je Aktie aus | VENLO (dpa-AFX) - Der Diagnostikspezialist und Labordienstleister Qiagen hat Details zu seinem sogenannten synthetischen Aktienrückkauf in Höhe von rund 300 Millionen US-Dollar bekanntgegeben. Je 36... ► Artikel lesen | |
| AMGEN | 263,50 | +0,29 % | Amgen Aktie: Starkes Wachstum sichert Zukunft | Die Amgen Aktie zeigt sich zum Jahresstart 2025 in robuster Verfassung. Der Biotechnologie-Konzern verzeichnete am 18. Januar einen Kursanstieg von 0,99% auf 272,11 USD. Besonders bemerkenswert ist... ► Artikel lesen | |
| NOVAVAX | 8,428 | -0,79 % | Novavax Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| MOLOGEN | - | - | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN A2DANN) mit Beständen bis zu 5.000 Euro Nominalwert können anteilige Vergütung des Gemeinsamen Vertreters zurückerhalten | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Anleihe/Sonstiges
Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,930 | +1,86 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 654,00 | +0,18 % | Cantor Fitzgerald Comments on REGN FY2025 Earnings | ||
| INOVIO PHARMACEUTICALS | 2,080 | -4,59 % | Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,040 | -3,61 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,900 | +9,02 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,302 | -0,16 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| KUROS BIOSCIENCES | 22,825 | -4,60 % | Adhoc: Kuros Biosciences AG: Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division | Kuros Biosciences AG / Key word(s): Agreement
Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division 07-Jan-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 59,20 | -0,60 % | BioMarin: Real-World Evidence Supports Safety, Efficacy Of VOXZOGO In Children With Achondroplasia | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced positive and consistent results from multiple real-world evidence studies of VOXZOGO (vosoritide) in children with achondroplasia.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,408 | +3,03 % | PTA-News: Small- & MicroCap Investment: Merck hat es vorgemacht: NurExone sichert sich Master Cell Bank | DJ PTA-News: Small- & MicroCap Investment: Merck hat es vorgemacht: NurExone sichert sich Master Cell Bank
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt (pta/19.01.2025/08:00) - Anfang... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 18,900 | -0,18 % | AKTIONÄR-Favorit Arrowhead Pharmaceuticals: Wichtiger Meilenstein | Gute Nachrichten von Arrowhead Pharmaceuticals am Freitagabend. Die US-Gesundheitsbehörde FDA hat den Antrag auf Marktzulassung des Unternehmens für Plozasiran zur Behandlung von Patienten mit einer... ► Artikel lesen | |
| XOMA ROYALTY | 26,400 | +4,76 % | XOMA AB: Xoma collaborates with Professor Christiane Funk at Umeå University on the FLOW (Filtration of Liquids and Organic Waste) technology |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,070 (-5,34 %) liegt der Kurs bei 1,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.
